Credits: Canva
From sleek devices masquerading as highlighters to flavor clouds drifting down school hallways, vaping has burst into a global phenomenon, particularly among teens. Although e-cigarettes were first pitched as a "healthier" alternative to smoking, recent research unearths a disturbing concoction of chemicals lurking beneath those saccharine-tasting plumes. A few are 13,000 times sweeter than sugar. Others? Acutely poisonous. With the increasing popularity of these artificial mixtures, we might be at the beginning of a new epidemic of public health one conceived by "flavoured lies.
Vaping devices currently reign supreme in the nicotine market, with more than 4.5 million constant consumers in the UK alone and countless more internationally. For teenagers, flavored disposable e-cigarettes such as "Blue Razz Ice" or "Killer Kustard" are the most common gateway. In the United States, according to a 2024 federal survey, 5.9% of middle-school and high-school students consume e-cigarettes, with the majority using flavored products.
This popularity is not by chance. The fruit, dessert, and sweet tastes cover up nicotine's bitterness and provide a sensory experience that simulates candy, soda, or gum. Some products feature artificial sweeteners such as neotame, a 7,000–13,000-fold sweeter compound than sugar. Neotame is safe for food use according to the FDA just not for inhaling. The effects of inhaling such a potent compound into sensitive lung tissue are unknown, but it's now available in almost every leading unregulated disposable vape brand.
A new study in JAMA tested 11 of the top-selling disposable e-vape brands—Elf Bar, Breeze, and Mr. Fog among them—and detected neotame in each and every one of them. What's more, the sweeteners were found even in vapes labeled "zero nicotine" or those with analogs, providing them with an even wider, youth appeal.
Scientists employed AI neural networks to model what occurs with the 180 flavor chemicals known when e-liquids are exposed to heat within a vape. The outcome? Alarming.
High temperatures cause dozens of new, toxic substances to emerge—most of which aren't even included in any label. These include:
These byproducts contain volatile carbonyls (VCs), a family of chemicals that have been shown to destroy the lungs and cause cancer. These were most prevalent in the fruit- and dessert-flavored versions the same versions that control youth tastes.
Though the FDA has approved just 34 e-cigarettes, all restricted to menthol or tobacco flavors, the other 86% of the U.S. vaping market contains technically illegal flavored products yet widely dispensed at convenience stores and gas stations. They are largely made in China, where flavored vapes were outlawed on the domestic market in 2022, pushing exports into overseas markets such as the United States.
The Supreme Court recently upheld the FDA's refusal to approve flavored vape applications on the grounds of their irresistible attraction to young consumers. But in reality, enforcement is still fragmented and non-functional, with illegal, flavored vapes falling through the cracks and into the backpacks of children.
The adolescent brain is particularly vulnerable to nicotine's impact, and specialists say that early exposure through vaping can have profound and long-lasting effects. Nicotine has been shown to modify the formation of neural pathways in teenagers, raising the likelihood of long-term dependence, diminishing cognitive ability and attention span, and even leading to mood disorders. There is also increasing worry that vaping is a gateway, that it's getting young people to move on to traditional smoking or to other drugs. But the threat is more than nicotine. Numerous youths who have never smoked are now regularly breathing in a mix of up to 180 chemical flavorings found in flavored vapes. These e-liquids include a combination of more than 180 flavoring chemicals, some of which were initially intended for consumption not inhalation.
When heated, they can transform into entirely new compounds, the health impacts of which are not yet fully understood. Unlike tobacco, which took decades to definitively link to lung cancer and heart disease, vaping is introducing unregulated, high-temperature chemicals into young lungs, creating a public health challenge whose full effects may only be known years from now. Most of the 180 flavor chemicals found in e-liquids are derived from the food industry. There, they are safe to consume. But inhale and heat them? A whole other story.
Chemicals such as diacetyl, which is characterized by its "buttery" taste, have already been associated with popcorn lung a serious but unusual type of lung disease. Researchers now fear that a series of long-term diseases will become reality in the next few decades as a result of extended exposure to vaping, particularly among individuals who started smoking e-cigarettes in their teens.
The inconsistency of vaping products also adds to the confusion. Variations in the design of batteries, temperature control, and e-liquids ensure that no two puffs are identical, so the health concerns become even more uncertain.
The charm of sweet, dessert-like vapes might seem innocent even exciting to some average teen but at the back of those flavors are chemicals never meant to be inhaled, and which could lead to health issues years later.
Credit: ProPublica
In a disturbing case from the US state of Florida, a pregnant woman in active labor was forced to attend a virtual court hearing via Zoom from her hospital bed for refusing a Cesarean delivery, also known as C-section — a common method of childbirth.
ProPublica reported that Cherise Doyley was in her 12th hour of contractions at the University of Florida Health facility, when she was, without her consent, made to sit in front of a host of people — a judge in a black robe and several lawyers, doctors, and hospital staff — for the Zoom proceeding.
While in active labor, a nurse came in with a bedsheet and told her to cover up, and a supervisor followed with a tablet.
“It’s a real judge in there?” Doyley asked the nurse at the beginning of what would be a three-hour hearing.
The mother of three, and a professional birthing doula, Doyley had arrived at the facility after her water broke.
While her doctors expressed concerns about the risk of uterine rupture —a potentially deadly complication for her and her baby — Doyley wanted to try for a vaginal delivery, as the risk was less than 2 percent, unless there was an emergency.
She told doctors she wouldn’t consent to a cesarean without trying to have a vaginal delivery first.
While the doctors initially relented, after several hours, she had to face a virtual court hearing, where the hospital and state attorney’s office forced Doyley to undergo a cesarean section.
Doyley has her own reasons to avoid a C-sec. She already had three prior C-sections, and one that resulted in a hemorrhage. She feared that a C-sec would lead to another serious complication and a lengthy recovery, and her kids would suffer.
However, the hospital was worried that her medical decisions may cause harm to the fetus, and that the courts may help decide which one mattered more, the report said.
Also read: Maternal Vaccination During Pregnancy Can Prevent COVID-related Hospitalization In Babies: Study
After three hours of testimony — all while Doyley lay in her hospital bed — the judge ruled that she could keep laboring unless there was an emergency. If that happened, the hospital could operate, whether she wanted it or not.
Overnight, doctors said the baby’s heart rate dropped for seven minutes. Doyley woke to her hospital bed being wheeled into surgery. The baby girl was delivered by C-section, the report said.
It is a surgical procedure that is used to deliver a baby through an incision made in the abdomen and uterus.
The method is preferred, especially in cases with complications during labor or breech presentation, or multiple births.
Unlike the popular conception, it hurts. In a vaginal delivery, the pain is experienced during labor and pushing, especially if done without an epidural.
Whereas, in a C-section, a surgery is performed that numbs the body from the chest down. However, the recovery could be painful and prolonged. It is also because in a C-section, it involves healing from a major abdominal surgery, while vaginal birth recovery may be quicker, more complicated, or traumatic.
Also read: 'Husband Stitch': A Medical Necessity Or Just A Tool To Objectify Women's Bodies?
Usually, it does not harm the baby, but there could be potential risks to the baby, including:
The American College of Obstetricians and Gynecologists (ACOG) advises against elective C-sections due to these potential complications.
Credit: iStock
American drugmaker Eli Lilly’s first oral pill for weight loss, Orforglipron, marketed as Foundayo, has been given the green signal by the US Food and Drug Administration (FDA).
Lilly is also known for injectable drugs like Zepbound for obesity and Mounjaro and Trulicity for diabetes.
Foundayo’s approval comes after the US FDA in December last year approved Novo Nordisk’s Wegovy pill — the first-ever GLP-1 pill for weight loss. The Danish drugmaker rolled out the pill in January this year.
Novo Nordisk was also the first to launch oral GLP 1 Rybelsus to treat type 2 diabetes. It was approved by the US FDA in September 2019.
Also Read: World Autism Awareness Day 2026: Can Cell Therapy Be The Future Of Autism Treatment?
In a statement, the US FDA said that "Foundayo has been approved for use in combination with a reduced-calorie diet and increased physical activity. The pill is targeted to reduce excess body weight and maintain weight reduction for the long term in adults with obesity or overweight".
Lilly said that the drug will be available from April 6 through its its direct-to-consumer platform LillyDirect at a cost of $149 per month for the lowest dose for self-pay customers — on par with Novo's pill. "Shortly after” it will be available through retail pharmacies and telehealth providers in the US.
"Today, fewer than 1 in 10 people who could benefit from a GLP-1 are taking one, held back by access, stigma, perceived complexity, or the belief that their condition isn't serious enough for treatment. We believe Foundayo can help level the playing field for those living with obesity or who are overweight and living with weight-related complications," said David A. Ricks, chair and CEO of Eli Lilly and Company.
"As a convenient, once-daily oral pill that delivers meaningful weight loss, this is obesity care designed for the real world," he added.
Also Read: Foundayo: US FDA Approves Eli Lilly’s GLP-1 Weight Loss Pill
In these trials, 72 weeks of treatment with Foundayo, in combination with a reduced-calorie diet and increased physical activity, resulted in a statistically significant and clinically meaningful reduction in body weight.

Deborah Horn, Director of the Center for Obesity Medicine at McGovern Medical School at UTHealth Houston, stated that Foundayo “delivered an average of 12.4 percent weight loss at the highest dose in clinical trials – addressing both the clinical realities of obesity and the practical challenges patients face every day."
In addition, Foundayo also led to reductions in many markers of cardiovascular risk, including waist circumference, non-HDL cholesterol, triglycerides, and systolic blood pressure across all doses, Eli Lilly said.
Lilly licensed Orforglipron, the main ingredient in Foundayo, from a Japanese pharmaceutical company in 2018.
As with the injectable forms of GLP-1s, Foundayo is available in six doses, ranging from 0.8mg to 17.2mg.
In consultation with their doctors, patients start with the lowest dose and gradually work up to higher doses; not everyone may need to reach the highest dose.
Also read: Eli Lilly's Experimental GLP-1 Pill Shows Promising Weight Loss
Unlike the Wegovy pill, people taking orforglipron do not need to restrict food or drink after taking the pill. Orforglipron is a small molecule that the body can absorb quickly and get into the blood, where it reaches the necessary tissues.
Foundayo is not safe for use in children and has an increased list of side effects, such as tumors in the thyroid, including thyroid cancer.
The drugmaker urged watching for possible symptoms, such as
Credit: Canva
New Zealand has stepped up surveillance after the first detection of a dengue and Zika-carrying mosquito larvae in the country.
The larval species was confirmed as 'Aedes aegypti' — known to carry diseases including dengue fever, yellow fever, Zika, and chikungunya, across the globe.
As New Zealand does not normally have the mosquito species, the larvae detected were counted as "exotic".
The mosquito species did not cause any outbreak, but were spotted during a routine surveillance program in Auckland.
"The National Public Health Service has commenced a heightened surveillance and interception programme following mosquito larvae being collected from a routine surveillance trap at Queens Wharf, Auckland, on Monday 30 March," Health New Zealand said in a statement.
Health New Zealand reported that exotic species were occasionally found at ports and airports.
The health body noted that the larvae were not considered a public health or biosecurity threat yet because there was no indication they had become established.
But the agency aimed to continue "intensive monitoring for at least three weeks".
"The monitoring would take place within a 400m radius of the site where the larvae were identified. Health Protection Officers would place mosquito traps in the survey area," the statement said.
"These have been hidden away from plain sight so they are not disturbed, for example, in old tyres, bushes, or pools of water. We ask members of the public to avoid touching or disturbing these traps if they find them, as it may disrupt our monitoring and trapping efforts," medical officer of health Dr David Sinclair said.
Sinclair said New Zealanders were most at risk from diseases transmitted by mosquitoes when travelling overseas, including to Pacific Island countries and territories where dengue fever was known to be present.
The US Centers for Disease Control and Prevention recently issued a travel alert of dengue outbreaks across 17 countries.
The CDC alert issued on March 23 identified 17 countries reporting an increased number of cases of dengue. These include: Afghanistan, Bangladesh, Bolivia, Colombia, Cook Islands, Cuba, Guyana, Maldives, Mali, Mauritania, New Caledonia, Pakistan, Samoa, Sudan, Timor-Leste, Vietnam, and the United States territories of American Samoa, Puerto Rico, and the US Virgin Islands, where local transmission is already common.
Also read: Long-term Exposure To Air Pollution Increases Fatality Rates In Dengue: Study
Dengue is a disease caused by a virus spread through mosquito bites. It is transmitted through infected mosquitoes, primarily the species Aedes aegypti.
The breakbone fever is caused by an infection with any of four different dengue viruses. These include:
• Dengue virus type 1 (DENV-1 or DEN-1)
• Dengue virus type 2 (DENV-2 or DEN-2)
• Dengue virus type 3 (DENV-3 or DEN-3)
• Dengue virus type 4 (DENV-4 or DEN-4)
Also read: New dengue vaccine over 80% effective, prevents severe disease for up to 5 years
Common Symptoms of dengue include:
• Sudden onset of high-grade fever.
• Intense headache
• Severe muscle, joint, or bone pain.
• Skin Rash that often appears 2–5 days after the fever starts
• Nausea and Vomiting
• Minor bleeding
• Fatigue.
© 2024 Bennett, Coleman & Company Limited